2019-08-15T08:18:24-05:00 2018-09-30 PricewaterhouseCoopers LLP 101 SEAPORT BLVD SUITE 500 BOSTON MA 02210 990 2017-10-01 042129889 Schepens Eye Research Institute Inc % CAROLANN WILLIAMS SCHE 6179120100 20 STANIFORD STREET Boston MA 02114 CAROLANN WILLIAMS CFO & VP FIN & ADMIN 6179120100 2019-08-12 true ERIN COUTURE P01390592 6175305000 2019-08-12 167.68.125.77 04363820192275000005 2019-08-15 P 502E9D7DF2DC237FB1436A97DBD0F14D19F2DD5A 21E2B2F0849F69D31DF4460457E3137BF9FA7202 2017 2019-02-21 02:37:17Z JOHN FERNANDEZ 243 CHARLES STREET BOSTON MA 02114 28781520 false X www.schepens.harvard.edu X 1950 MA SEE SCHEDULE O. 14 11 178 18 0 29219 19299029 21393495 1888652 2000156 663684 4032972 2012715 1346097 23864080 28772720 191611 228372 0 0 14136752 17473056 0 0 0 11487519 11168515 25815882 28869943 -1951802 -97223 61005170 81562366 43276818 64399539 17728352 17162827 X SEE SCHEDULE O false false 20427652 228372 2809777 The Institute has research at every stage of development from the critical new ideas that are changing the way researchers around the world look at the future of treatment, to products in late-stage clinical trials, set to make an immediate impact on the lives of people struggling with vision-robbing diseases and injuries. The Institute has made tremendous progress in developing new cures for macular degeneration, diabetic retinopathy, glaucoma, other types of retinal and optic nerve degenerations and damage, dry eye and eye tissue transplants. There have also been great strides made in the development of new technologies - new lenses and devices - to help those with low vision make the absolute most out of the vision they have until we can reverse vision loss. 20427652 true true false false false false false false false true true false false true true true false true false false true false false false false false false true false true false false false false false false false false true false false false false true true true false false true 33 0 true 178 true true true false false false false false false false false false X 14 11 false false false false true true true true true false false true true true true true true false false false MA X X CAROLANN WILLIAMS 6175733424 20 STANIFORD STREET Boston MA 02114 X MARK ABELSON DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 WILLIAM AIKMAN DIRECTOR 4.0 0.0 X 0 0 0 DEWALT PETE ANKENY DIRECTOR 4.0 4.0 X 0 0 0 KENNETT BURNES CHAIRMAN 4.0 0.0 X X 0 0 0 CHARLES DE GUNZBERG DIRECTOR 4.0 4.0 X 0 0 0 JOHN FERNANDEZ PRESIDENT 4.0 56.0 X X 0 1143642 229175 KENNETH FISCHER DIRECTOR 4.0 0.0 X 0 0 0 GERARD GOLDSTEIN DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 WYCLIFFE K GROUSBECK DIRECTOR 4.0 6.0 X 0 0 0 DONALD KORB DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 KAY LYONS DIRECTOR 4.0 0.0 X 0 0 0 RENEE MANGER DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 VICTORIA MCCULLOUGH DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 JOAN W MILLER MD DIRECTOR 4.0 56.0 X 0 904826 148157 ANNETTE NOVA DIRECTOR (UNTIL 12/17) 4.0 4.0 X 0 0 0 PATRICIA PATRICELLI DIRECTOR 4.0 0.0 X 0 0 0 JOHN REILLY DIRECTOR 4.0 0.0 X 0 0 0 JOSEPH RIZZO MD DIRECTOR 4.0 56.0 X 0 439795 58175 SHERMAN STARR DIRECTOR (UNTIL 12/17) 4.0 0.0 X 0 0 0 FRANS VAN DE VELDE DIRECTOR 4.0 0.0 X 0 0 0 KATHRYN VECELLIO DIRECTOR 4.0 0.0 X 0 0 0 MARTHA PYLE FARRELL ASSISTANT SECRETARY 4.0 56.0 X 0 399988 25895 LYLE HOWLAND SECRETARY 4.0 4.0 X 0 0 0 JONATHAN UHRIG TREASURER 4.0 6.0 X 0 0 0 MAUREEN KELLEY ASSISTANT SECRETARY 4.0 56.0 X 0 196400 21289 CAROLANN WILLIAMS CFO AND VP FINANCE & ADMIN 4.0 56.0 X 0 491994 18998 DEBRA ROGERS VP OPTHALMOLOGY 10.0 50.0 X 0 301334 16757 PATRICIA D'AMORE DIRECTOR OF RESEARCH 60.0 0.0 X 0 415680 44459 LOTFI MERABET ASSOCIATE SCIENTIST 60.0 0.0 X 0 157751 25631 ELIEZER PELI SENIOR SCIENTIST 60.0 0.0 X 0 248032 45134 DARLENE DARTT SENIOR SCIENTIST 60.0 0.0 X 0 173995 34611 JAMES ZIESKE SENIOR SCIENTIST 60.0 0.0 X 0 145833 28703 NEENA HAIDER ASSOCIATE SCIENTIST 60.0 0.0 X 0 140364 37192 0 5159634 734176 0 false true false 0 755749 18015403 2622343 31519 21393495 SERI CORE SERVICE CHARGES 900099 2000156 2000156 2000156 369593 369593 0 365780 365780 179496 8800 170696 0 170696 170696 3663379 3663379 3663379 3663379 0 0 0 0 0 0 0 0 0 PARKING INCOME 531390 33720 33720 OTHER REVENUE 775901 775901 809621 28772720 2809777 4569448 228372 228372 0 0 0 410856 410856 0 12999146 9131074 3868072 872285 612725 259560 2508781 1762259 746522 681988 479053 202935 0 13143 10127 3016 33282 18047 15235 0 0 43532 43532 545768 227555 318213 24904 17733 7171 4069225 3928702 140523 296363 296363 0 -14841 -14841 0 3647324 1893264 1754060 346497 342552 3945 0 101225 82432 18793 346646 346646 0 1045381 669044 376337 77829 77829 PROCESSING AND FILING FEES 128047 125297 2750 MEMBERSHIP DUES 37361 36936 425 MISCELLANEOUS 205307 170102 35205 REIMB/MEEI/EMP&BENEFITS 221522 221522 28869943 20427652 8442291 0 4882166 5659887 0 0 4939011 4986003 0 0 0 0 0 0 0 0 0 0 37576 18183 72634413 54963119 17435828 17671294 0 0 2164978 2187605 0 0 646992 768476 30898619 50270918 61005170 81562366 2026449 842613 0 0 4848398 5844819 7762512 0 0 0 0 0 0 0 0 0 28639459 57712107 43276818 64399539 X 677074 -2679718 5039560 7830827 12011718 12011718 17728352 17162827 61005170 81562366 X -97223 -468302 X false true X true true true X 20437991 22555238 19206800 19299029 21393495 102892553 0 0 20437991 22555238 19206800 19299029 21393495 102892553 1460044 101432509 972710 576213 801464 1770743 914869 5035999 0 428192 377808 302477 554961 809621 2473059 110401611 7465622 0.91876 0.93784 X 14705511 3408658 903733 43310 17167126 16650248 903925 2778490 70172 14705511 17908169 671006 1859411 69516 16650248 20014836 73836 2091049 89454 17908169 25009323 1351690 6242831 103346 20014836 false true true 202819 202819 42670241 27284645 15385596 8423353 8360827 62526 20750382 19317647 1432734 587618 587618 17671294 DUE FROM AFFILIATES 50251469 OTHER ASSETS 19449 50270918 0 DUE TO AFFILIATES 50260544 OTHER LIABILITIES 799785 SERI FRAMEWORK LOAN LONG TERM 6651778 57712107 X SCHEDULE D, PART V, LINE 4 THE INTENDED USE OF SCHEPENS' ENDOWMENT FUNDS IS TO PROVIDE A PREDICTABLE STREAM OF FUNDING TO THE SUPPORTED RESEARCH ACTIVITIES WHILE SEEKING TO MAINTAIN THE PURCHASING POWER OF THE ENDOWMENT ASSETS. SCHEDULE D, PART X, LINE 2 SCHEPENS EYE RESEARCH INSTITUTE, INC. ("SCHEPENS") WAS INCLUDED IN CONSOLIDATED FINANCIAL STATEMENTS WITH ITS AFFILIATED ORGANIZATIONS. THE INCOME TAX FOOTNOTE IS AS FOLLOWS: THE FOUNDATION AND ITS AFFILIATES QUALIFY AS TAX-EXEMPT ORGANIZATIONS UNDER THE INTERNAL REVENUE CODE. THE FOUNDATION, INFIRMARY, ASSOCIATES, SCHEPENS AND EMBANKMENT ARE TAX-EXEMPT UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND CIRCLE IS TAX-EXEMPT UNDER 501(C)(25) OF THE INTERNAL REVENUE CODE. ACCORDINGLY, NO PROVISION FOR INCOME TAXES HAS BEEN MADE IN THE ACCOMPANYING FINANCIAL STATEMENTS. MANAGEMENT HAS EVALUATED ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES AND THERE WAS NO IMPACT TO THE FOUNDATION'S FINANCIAL STATEMENTS FOR THE YEAR ENDED SEPTEMBER 30, 2018. true Europe (Including Iceland and Greenland) Program Services CONFERENCES 36973 East Asia and the Pacific Program Services CONFERENCES 18999 Middle East and North Africa Program Services CONFERENCES 6885 South America Program Services CONFERENCES 2714 65571 65571 false false false false false false true Duke University 2200 W Main Street Erwin Square Plaza Suite 820 Durham NC 22705 560532129 501(C)(3) 34944 RESEARCH Boston Children's Hospital 300 Longwood Avenue Boston MA 02115 042774441 501(c)(3) 51478 RESEARCH Tufts University 136 Harrison Avenue Boston MA 021111817 042103634 501(c)(3) 12152 RESEARCH University of Nebraska Medical Center 984388 NE Med Center Lincoln NE 681984388 470049123 501(c)(3) 49795 RESEARCH University of Pittsburgh 123 University Pl B21 Pittsburgh PA 15213 259065591 501(c)(3) 12109 RESEARCH Metis Foundation 300 Convent St S 1330 San Antonio TX 78205 422219464 510(c)(3) 67893 RESEARCH 6 Schedule I, Part I, Line 2 Subawards are issued through a consortium agreement between Schepens Eye Research Institute ("SERI") and the recipient institution. The agreement specifies the terms of the subaward, and includes a detailed budget and scope of work to be performed by the recipient institution. Awarded funds are encumbered by a purchase order that is assigned to a unique fund number. Payments to recipient institutions made against the purchase order are recorded in the accounting system so that individual payments and purchase order balances can be monitored. Disbursement of funds for subawards require the written approval of the Principal Investigator ("PI"). Frequent progress reports and other forms of communication are required between the PI and the subrecipient institute to ensure that the scope of work is progressing at a satisfactory pace. Research Administration also conducts an annual inventory of institutions to which research has been subawarded. A risk assessment matrix is employed, along with a review of the subrecepient's most recent A133 audit report, to determine the level of risk regarding the sub recepient's ability to comply with federal guidelines. false true false false false false false false false JOHN FERNANDEZ PRESIDENT 0 742730 0 174465 0 226447 0 209674 0 19501 0 1372817 0 150000 JOAN W MILLER MD DIRECTOR 0 753644 0 128076 0 23106 0 136840 0 11317 0 1052983 0 0 JOSEPH RIZZO MD DIRECTOR 0 388779 0 29400 0 21616 0 36840 0 21335 0 497970 0 0 MARTHA PYLE FARRELL ASSISTANT SECRETARY 0 327122 0 52544 0 20322 0 6423 0 19472 0 425883 0 0 DEBRA ROGERS VP OPTHALMOLOGY 0 241740 0 39795 0 19799 0 5315 0 11442 0 318091 0 0 PATRICIA D'AMORE DIRECTOR OF RESEARCH 0 393189 0 0 0 22491 0 36840 0 7619 0 460139 0 0 LOTFI MERABET ASSOCIATE SCIENTIST 0 157204 0 0 0 547 0 19160 0 6471 0 183382 0 0 ELIEZER PELI SENIOR SCIENTIST 0 245058 0 0 0 2974 0 32549 0 12585 0 293166 0 0 DARLENE DARTT SENIOR SCIENTIST 0 172083 0 0 0 1912 0 22392 0 12219 0 208606 0 0 JAMES ZIESKE SENIOR SCIENTIST 0 144408 0 0 0 1425 0 16624 0 12079 0 174536 0 0 NEENA HAIDER ASSOCIATE SCIENTIST 0 140056 0 0 0 308 0 17163 0 20029 0 177556 0 0 MAUREEN KELLEY ASSISTANT SECRETARY 0 177987 0 1500 0 16913 0 2020 0 19269 0 217689 0 0 CAROLANN WILLIAMS CFO AND VP FINANCE & ADMIN 0 426681 0 64503 0 810 0 4315 0 14683 0 510992 0 0 SCHEDULE J, PART I, LINE 3 OFFICERS, DIRECTORS, & KEY EMPLOYEES OF SCHEPENS EYE RESEARCH INSTITUTE, INC. ("SCHEPENS") ARE COMPENSATED BY THE MASSACHUSETTS EYE AND EAR INFIRMARY ("THE INFIRMARY"), ONE KEY EMPLOYEE IS PAID BY THE MASSACHUSETTS EYE AND EAR ASSOCIATES, AND ONE DIRECTOR IS PAID BY THE MASSACHUSETTS EYE AND EAR ASSOCIATES. BOTH ARE RELATED ORGANIZATIONS. THE INFIRMARY USED A COMPENSATION COMMITTEE, COMPENSATION SURVEY, APPROVAL BY THE BOARD, AND AN INDEPENDENT COMPENSATION CONSULTANT TO ESTABLISH THE COMPENSATION OF THE PRESIDENT. SCHEDULE J, PART I, LINE 4B CERTAIN INDIVIDUALS PARTICIPATE IN A DEFERRED COMPENSATION ARRANGEMENT WITH MASSACHUSETTS EYE AND EAR. UNDER THIS AGREEMENT, JOHN FERNANDEZ WILL BE CREDITED $200,000 FOR CALENDAR YEAR 2017. JOAN MILLER WILL BE CREDITED $100,000 FOR CALENDAR YEAR 2017. EACH ANNUAL CREDIT WILL VEST ON THE FOURTH ANNIVERSARY OF THE DATE SUCH CREDIT WAS MADE OR UPON (1) THE ATTAINMENT OF THE AGE OF 65 WHILE EMPLOYED; (2) TERMINATION WITHOUT CAUSE OR RESIGNATION FOR GOOD REASON; (3) DEATH; (4) DISABILITY; OR (5) CHANGE OF CONTROL OF MASSACHUSETTS EYE AND EAR WITHIN THE MEANING OF SECTION 409A OF THE INTERNAL REVENUE CODE. MR. FERNANDEZ RECEIVED A PAYOUT OF $195,795 FROM THE DEFERRED COMPENSATION AGREEMENT IN 2017. X 5 31519 FMV false true false Schedule M, Part I, Column (B) SCHEPENS IS REPORTING THE NUMBER OF CONTRIBUTIONS RECEIVED DURING THE YEAR. Form 990, Part I, Line 1 & PART III, LINE 1 DESCRIPTION OF ORGANIZATION MISSION THE SCHEPENS EYE RESEARCH INSTITUTE ("SCHEPENS") FIGHTS BLINDNESS BY DEVELOPING NEW TECHNOLOGIES, THERAPIES AND KNOWLEDGE TO RETAIN AND RESTORE VISION. THROUGH A CONTINUUM OF DISCOVERY, THE INSTITUTE WORKS TOWARD A FUTURE IN WHICH BLINDNESS IS PREVENTED, ALLEVIATED AND ULTIMATELY CURED. Form 990, Part VI, Section A, line 6 THE FOUNDATION OF THE MASSACHUSETTS EYE AND EAR INFIRMARY, INC. IS THE SOLE MEMBER OF THE INSTITUTE. Effective April 1, 2018, Partners Healthcare System, Inc.(Partners) became the sole member of the Foundation. As a result the Foundation and its affiliated entities became part of the comprehensive, integrated healthcare system organized and operated by Partners that includes hospitals, physicians, charitable, scientific, educational, research and other Partners affiliated organizations. FORM 990, PART VI, SECTION A, LINE 7A THE BOARD OF DIRECTORS ARE ELECTED BY THE MEMBER. FORM 990, PART VI, SECTION A, LINE 7B The following actions shall require approval by the Member: 1. Approval of all long-term or master strategic or business plans of the Corporation and any substantive changes thereto; 2. Approval of any substantive changes to the vision and mission statement of the Corporation; 3. Approval of annual and long-term operating and capital budgets of the Corporation; 4. Approval of the merger, consolidation, or dissolution of the Corporation; 5. Approval of any material change in the types of research conducted by the Corporation, including additions thereto and discontinuations thereof, which are not expressly identified and provided for in the previously approved strategic and/or business plans; 6. Appointment or removal of financial auditors of the Corporation; 7. Approval of the Corporations plan of insurance; 8. Approval of the organization or acquisition of any subsidiary or affiliate of the Corporation, or the conducting of all or any part of the Corporations business through one or more affiliated corporations, partnerships, limited liability companies or other arrangements or entities; 9. Approval of any academic or other material strategic affiliation of the Corporation with third parties. Form 990, part VI, Section B, line 11B SCHEPENS'S FORM 990 IS PREPARED BY PRICEWATERHOUSECOOPERS, LLP USING INFORMATION PROVIDED BY MANAGEMENT. AFTER THE FORM 990 IS COMPLETED, IT IS REVIEWED BY THE MANAGER OF INVESTMENTS AND FOUNDATION ACCOUNTING. THE FORM 990 IS THEN PRESENTED TO THE FINANCE COMMITTEE FOR FURTHER REVIEW AND APPROVAL AS AUTHORIZED BY THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS IS ALSO GIVEN THE FORM 990 FOR REVIEW WITH TIME TO SUBMIT COMMENTS AND QUESTIONS BEFORE FINAL FILING. FORM 990, Part VI, Section B, Line 12C SCHEPENS EMPLOYEES ARE COVERED BY THE INFIRMARY CONFLICT OF INTEREST POLICY. MEMBERS OF THE STAFF ARE REQUIRED TO DISCLOSE CONFLICTS OF INTEREST TO THEIR CHIEF OF SERVICE, DEPARTMENT AND DIRECTOR OF LABORATORY/UNIT. MEMBERS OF THE BOARD OF DIRECTORS ARE REQUIRED TO DISCLOSE ANNUALLY, IN WRITING, ANY INTERESTS THAT COULD RISE TO CONFLICTS. THE OFFICE OF THE INTERNAL LEGAL COUNSEL OBTAINS AND REVIEWS THE ANNUAL CONFLICTS OF INTEREST STATEMENTS SUBMITTED BY MEMBERS OF THE BOARD OF DIRECTORS, AND REPORTS ON THE SAME TO THE AUDIT AND COMPLIANCE COMMITTEE OF THE BOARD. WITH RESPECT TO INTERESTS DISCLOSED BY THE BOARD MEMBERS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST, THE INTERNAL LEGAL COUNSEL REVIEWS ALL TRANSACTIONS BETWEEN SUCH INTERESTS AND AFFILIATES OF SCHEPENS, TO DETERMINE WHETHER THESE TRANSACTION WERE CONDUCTED AT ARM'S LENGTH. FORM 990, Part VI, Section B, Line 15 PLEASE SEE THE INFIRMARY'S RETURN FOR COMPENSATION DISCLOSURES. THE CHAIRMAN OF THE COMPENSATION COMMITTEE OF THE BOARD OF THE MASSACHUSETTS EYE AND EAR INFIRMARY PRESENTS A RECOMMENDATION TO THE COMPENSATION COMMITTEE WHO HAVE FINAL APPROVAL OF THE CEO'S BASE SALARY AND BONUS AMOUNT. THE CEO RECOMMENDS EXECUTIVE SALARIES TO THE COMPENSATION COMMITTEE OF THE BOARD WHO HAS FINAL AUTHORIZATION TO APPROVE IT. THE COMPENSATION COMMITTEE MEETING WAS HELD ON NOVEMBER 15, 2017. TOTAL COMPENSATION FOR THE CEO, CHIEFS AND VICE PRESIDENTS, INCLUDING BONUS PAYMENTS, INCLUDING COMPARABILITY DATA, IS ANALYZED BY INDEPENDENT COMPENSATION CONSULTANTS AND IS DETERMINED TO BE REASONABLE. FORM 990, PART VI, SECTION B, LINE 19 SUMMARIZED FINANCIAL STATEMENTS ARE AVAILABLE ON THE INFIRMARY'S WEBSITE: WWW.MASSEYEANDEAR.ORG. AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. SCHEPENS' GOVERNING DOCUMENTS AND FORM 990 ARE AVAILABLE UPON REQUEST. THE CONFLICT OF INTEREST POLICY IS ALSO AVAILABLE UPON REQUEST. FORM 990, Part VII COMPENSATION IS FOR PROFESSIONAL SERVICES AND NOT FOR SERVICE AS OFFICERS. PLEASE SEE THE INFIRMARY'S RETURN FOR COMPENSATION DISCLOSURES. FND OF THE MASS EYE & EAR INFIRMARY INC 243 Charles Street Boston MA 02114 042785453 SUPPORT MA 501(C)(3) 10 PHS false Massachusetts Eye and Ear Infirmary 243 Charles Street Boston MA 02114 042103591 Hospital MA 501(C)(3) 3 Foundation true Massachusetts Eye and Ear AssociatesInC 243 Charles Street Boston MA 02114 222658209 Patient care MA 501(C)(3) 10 Foundation true Embankment Services Inc 243 CHARLES STREET Boston MA 02114 043272965 Support MA 501(C)(3) 12 Type 1 Foundation true Circle Company Inc 243 Charles Street Boston MA 02114 042801791 TITLE HOLDING MA 501(C)(25) n/a Foundation true PARNTERS HEALTHCARE SYSTEM INC (PHS) 800 BOYLSTON STREET BOSTON MA 02199 043230035 HOSPITAL MA 501(C)(3) 3 NA false PARTNERS HEALTHCARE GROUP (SEE PART VII) 800 BOYLSTON STREET BOSTON MA 02199 HEALTHCARE ME 501(c)(3) 10 PHS true NEIGHBORHOOD HEALTH PLAN INC (NHP) 253 Summer Street BOSTON MA 02210 042932021 INSURANCE MA 501(c)(4) NONE PHS true COMMUNITY MEDICAL ALLIANCE INC 253 Summer Street BOSTON MA 02210 043454185 INSURANCE MA 501(c)(3) 12A NHP true PARTNERS POOLED INVESTMENT HOLDINGS LLC 800 BOYLSTON STREET BOSTON MA 02199 821715859 SUPPORT ORG. MA 501(C)(3) 12A PHS true PHS BAY COLONY FUND 245 Park Avenue NEW YORK NY 10167 133887448 INVESTMENTS DE NA N/A PARTNERS HEALTHCARE SYSTEM POOLED INVEST 101 MERRIMAC STREET BOSTON MA 02114 043268842 INVESTMENTS MA NA N/A RADIATION THERAPY OF SOUTEASTERN MA LLC 375 LONGWOOD AVENUE BOSTON MA 02115 010873580 RADIATION THERAPY MA NA N/A PARTNERS INNOVATION FUND LLC 101 HUNTINGTON AVENUE BOSTON MA 02199 262899986 INVESTMENTS MA NA N/A PARTNERS HEALTHCARE ACCOUNTABLE CARE ORG 399 REVOLUTION DRIVE SOMERVILLE MA 02145 812762122 ACCOUNTABLE CARE MA NA N/A NEWTON-WELLESLEY PHYSICAN HOSPITAL ORG 2014 Washington Street NEWTON MA 02462 043209749 HEALTHCARE MA NA SUBCH. C CORP ALLWAYS HEALTH PARTNERS INSURANCE CO 399 REVOLUTION AVE SOMERVILLE MA 02145 830970929 INSURANCE COMPANY MA NA SUBCH. C CORP. false true true false false false false false false false false false false false false true true false false MASSACHUSETTS EYE AND EAR INFIRMARY C 409706 CASH MASSACHUSETTS EYE AND EAR INFIRMARY P 438533 CASH MASSACHUSETTS EYE AND EAR INFIRMARY Q 1874604 CASH MASSACHUSETTS EYE AND EAR INFIRMARY C 271961 CASH MASSACHUSETTS EYE AND EAR INFIRMARY Q 255470 CASH MASSACHUSETTS EYE AND EAR ASSOCIATES P 4299232 CASH SCHEDULE R, PART II EFFECTIVE APRIL 1, 2018, THE ORGANIZATION BECAME RELATED TO PARTNERS HEALTHCARE SYSTEM, INC. AND ITS RELATED ENTITIES IN ITS GROUP EXEMPTION. EFFECTIVE OCTOBER 1, 2018, THE ORGANIZATION BECAME PART OF THE PARTNERS GROUP EXEMPTION.